Watanabe-Fujinuma E, Banderas BF, Koretsune Y, Kumagai K, Uchiyama S, Yamashita T, Yasaka M, Akiyama S, Briere JB, Dickie G, Cano SJ. Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation. Journal of medical economics. 2019;22(8):798-805.
Koretsune Y, Kumagai K, Uchiyama S, Yamashita T, Yasaka M, Watanabe-Fujinuma E, et al. Patient-reported treatment satisfaction with rivaroxaban in Japanese non-valvular atrial fibrillation patients: an observational study. Current medical research and opinion. 2018:1-8.
Cano S, Mantovani L, Folkerts K, Gebel M, Sahin K, Zell E, et al. Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis. TH Open. 2018;02(02):e139-e46.
Diab M, Bilkhu R, Soppa G, McGale N, Hirani SP, Newman SP, et al. Quality of Life in Relation to Length of Intensive Care Unit Stay After Cardiac Surgery. Journal of cardiothoracic and vascular anesthesia. 2017;31(3):1080-90.
Beaney KE, Ward CE, Bappa DA, McGale N, Davies AK, Hirani SP, et al. A 19-SNP coronary heart disease gene score profile in subjects with type 2 diabetes: the coronary heart disease risk in type 2 diabetes (CoRDia study) study baseline characteristics. Cardiovascular diabetology. 2016;15(1):141.
Prins MH, Bamber L, Cano SJ, Wang MY, Erkens P, Bauersachs R, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thrombosis research. 2015;135(2):281-8.
Diab M, Soppa G, McGale N, Hirani SP, Newman S, Jahangiri M. Quality of Life and functional status following cardiac surgery. Society for Cardiothoracic Surgery in Great Britain and Ireland; Manchester, UK, 2015.
Davies AK, McGale N, Humphries SE, Hirani SP, Beaney KE, Bappa DA, et al. Effectiveness of a self-management intervention with personalised genetic and lifestyle-related risk information on coronary heart disease and diabetes-related risk in type 2 diabetes (CoRDia): study protocol for a randomised controlled trial. Trials. 2015;16:547.
Sosner P, Fiquet B, Quere S, Francillon A, Herpin D. How are physicians prescribing the direct renin inhibitor aliskiren in the management of essential hypertension? A French observational study. Journal of hypertension. 2013;31(7):1491-6; discussion 6.
Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC. Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health QualLife Outcomes. 2013;11(1):161.
Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AW, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thrombosis and haemostasis. 2013;110(4):732-41.
Mounier-Vehier C, Simon T, Guedj-Meynier D, Ferrini M, Ghannad E, Hubermann JP, et al. Gender-related differences in the management of hypertension by cardiologists: the PARITE study. Archives of cardiovascular diseases. 2012;105(5):271-80.
Cano SJ, Lamping DL, Bamber L, Smith S. The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes. 2012;10:120.
Cano S, Bamber L, Lamping D. Comparing oral rivaroxaban versus standard treatment in the treatment of symptomatic deep vein thrombosis: a patient-reported treatment satisfaction study. 17th Congress of the European association of hospital pharmacists; Milan, Italy, 2012.
Asmar R, Gosse P, Quere S, Achouba A. Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. Blood pressure monitoring. 2011;16(2):80-6.
Marquis P, Le Gal M, Francillon A, Andre-Fouet X. [Quality of life and angina pectoris. Comparison of the effects of 2 nitrate derivatives administered discontinuously: transdermal 10 mg nitroglycerine patch (12 hours) and long-acting oral 40 mg isosorbide-5-mononitrate (once a day)]. Ann Cardiol Angeiol (Paris). 2001;50(6):340-50.
Marquis P, Comte S, Lehert P. International validation of the CLAU-S quality-of-life questionnaire for use in patients with intermittent claudication. Pharmacoeconomics. 2001;19(6):667-77.
Selke B, Marquis P, Lebrun T. [Socioeconomic and quality of life repercussions of arterial hypertension]. Drugs. 1998;56 Suppl 2:45-53.
Marquis P, Fayol C, Joire JE, Leplege A. Psychometric properties of a specific quality of life questionnaire in angina pectoris patients. Qual Life Res. 1995;4(6):540-6.
Marquis P, Fayol C, Joire JE. Clinical validation of a quality of life questionnaire in angina pectoris patients. Eur Heart J. 1995;16(11):1554-60.
Marquis P, Fayol C, McCarthy C, Fiessinger JN. [Measurement of quality of life in intermittent claudication. Clinical validation of a questionnaire]. Presse Med. 1994;23(28):1288-92.